Bank of New York Mellon
SGMO

Bank of New York Mellon’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Bank of New York Mellon’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-49,772
Closed -$12.3K – 4414
2026
Q1 		$12.3K Buy
49,772
+27,505
+124% +$10.9K ﹤0.01% 4183
2025
Q4 		$9.35K Hold
22,267
– – ﹤0.01% 4177
2025
Q3 		$15K Hold
22,267
– – ﹤0.01% 4165
2025
Q2 		$12.1K Hold
22,267
– – ﹤0.01% 4126
2025
Q1 		$14.6K Hold
22,267
– – ﹤0.01% 4096
2024
Q4 		$22.7K Buy
22,267
+7,757
+53% +$14.2K ﹤0.01% 4102
2024
Q3 		$12.6K Hold
14,510
– – ﹤0.01% 4077
2024
Q2 		$5.2K Sell
14,510
-458,602
-97% -$248K ﹤0.01% 4111
2024
Q1 		$317K Sell
473,112
-23,276
-5% -$16.9K ﹤0.01% 3755
2023
Q4 		$270K Sell
496,388
-4,953
-1% -$2.28K ﹤0.01% 3842
2023
Q3 		$301K Sell
501,341
-8,499
-2% -$9.1K ﹤0.01% 3797
2023
Q2 		$663K Buy
509,840
+9,708
+2% +$13.3K ﹤0.01% 3443
2023
Q1 		$880K Buy
500,132
+1,998
+0.4% +$5.7K ﹤0.01% 3191
2022
Q4 		$1.56M Sell
498,134
-15,359
-3% -$59.6K ﹤0.01% 2974
2022
Q3 		$2.52M Buy
513,493
+51,585
+11% +$265K ﹤0.01% 2691
2022
Q2 		$1.91M Buy
461,908
+18,718
+4% +$80.9K ﹤0.01% 2852
2022
Q1 		$2.58M Buy
443,190
+4,035
+0.9% +$24K ﹤0.01% 2800
2021
Q4 		$3.29M Buy
439,155
+3,058
+0.7% +$26.6K ﹤0.01% 2689
2021
Q3 		$3.93M Buy
436,097
+31,274
+8% +$309K ﹤0.01% 2606
2021
Q2 		$4.85M Sell
404,823
-85,063
-17% -$963K ﹤0.01% 2507
2021
Q1 		$6.14M Sell
489,886
-18,616
-4% -$251K ﹤0.01% 2353
2020
Q4 		$7.93M Sell
508,502
-20,449
-4% -$240K ﹤0.01% 2124
2020
Q3 		$5M Sell
528,951
-14,534
-3% -$157K ﹤0.01% 2217
2020
Q2 		$4.87M Buy
543,485
+28,840
+6% +$268K ﹤0.01% 2218
2020
Q1 		$3.28M Buy
514,645
+5,858
+1% +$43.5K ﹤0.01% 2288
2019
Q4 		$4.26M Sell
508,787
-3,094
-0.6% -$28.4K ﹤0.01% 2412
2019
Q3 		$4.63M Buy
511,881
+6,625
+1% +$74.3K ﹤0.01% 2319
2019
Q2 		$5.44M Buy
505,256
+35,809
+8% +$381K ﹤0.01% 2287
2019
Q1 		$4.48M Buy
469,447
+5,802
+1% +$59.3K ﹤0.01% 2384
2018
Q4 		$5.32M Buy
463,645
+8,910
+2% +$111K ﹤0.01% 2251
2018
Q3 		$7.71M Buy
454,735
+7,472
+2% +$114K ﹤0.01% 2177
2018
Q2 		$6.35M Sell
447,263
-16,585
-4% -$275K ﹤0.01% 2265
2018
Q1 		$8.81M Buy
463,848
+71,135
+18% +$1.52M ﹤0.01% 2043
2017
Q4 		$6.44M Buy
392,713
+18,404
+5% +$274K ﹤0.01% 2225
2017
Q3 		$5.61M Buy
374,309
+34,467
+10% +$381K ﹤0.01% 2286
2017
Q2 		$2.99M Buy
339,842
+6,537
+2% +$41.9K ﹤0.01% 2597
2017
Q1 		$1.73M Buy
333,305
+19,142
+6% +$76.8K ﹤0.01% 2926
2016
Q4 		$958K Sell
314,163
-78
-0% -$284 ﹤0.01% 3283
2016
Q3 		$1.46M Sell
314,241
-3,022,300
-91% -$15.4M ﹤0.01% 2964
2016
Q2 		$19.3M Sell
3,336,541
-22,790
-0.7% -$145K 0.01% 1426
2016
Q1 		$20.3M Buy
3,359,331
+1,466,593
+77% +$8.81M 0.01% 1399
2015
Q4 		$17.3M Sell
1,892,738
-54,885
-3% -$423K 0.01% 1480
2015
Q3 		$11M Buy
1,947,623
+67,696
+4% +$558K ﹤0.01% 1811
2015
Q2 		$20.8M Buy
1,879,927
+105,856
+6% +$1.36M 0.01% 1462
2015
Q1 		$27.8M Buy
1,774,071
+206,179
+13% +$3.19M 0.01% 1258
2014
Q4 		$23.8M Buy
1,567,892
+1,201,578
+328% +$14.6M 0.01% 1337
2014
Q3 		$3.95M Sell
366,314
-2,682
-0.7% -$35K ﹤0.01% 2457
2014
Q2 		$5.63M Buy
368,996
+19,106
+5% +$275K ﹤0.01% 2263
2014
Q1 		$6.33M Buy
349,890
+32,077
+10% +$618K ﹤0.01% 2183
2013
Q4 		$4.42M Buy
317,813
+37,308
+13% +$430K ﹤0.01% 2375
2013
Q3 		$2.94M Buy
280,505
+18,853
+7% +$187K ﹤0.01% 2582
2013
Q2 		$2.04M Buy
+261,652
New +$2.28M ﹤0.01% 2776

Other funds holding SGMO

Simplex Trading
Simplex Trading Chicago, Illinois $171B AUM 85% 1-Year Est. Return
AIM
Axiom Investment Management New York $150M AUM
HIG
Heritage Investment Group Pompano Beach, Florida $744M AUM 20.51% 1-Year Est. Return

Bank of New York Mellon's SGMO Position: Q2 2026 in Review

Bank of New York Mellon sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q2 2026, closing a stake of 49,772 shares — an estimated $12.3K sold.

Bank of New York Mellon first reported a position in SGMO in Q2 2013 and held it in 52 quarters. The position peaked at $27.8M in Q1 2015. 3 funds tracked by Wall St. Rank hold SGMO as of Q2 2026.

  • Bank of New York Mellon reported no remaining SANGAMO THERAPEUTICS INC position as of Q2 2026 after selling out during the quarter.
  • Bank of New York Mellon sold 49,772 SANGAMO THERAPEUTICS INC shares in Q2 2026, an estimated $12.3K.
  • Bank of New York Mellon first reported a position in SANGAMO THERAPEUTICS INC in Q2 2013 and held it in 52 quarters.
  • Bank of New York Mellon's SANGAMO THERAPEUTICS INC position peaked at $27.8M in Q1 2015.
  • 3 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.